Follow on Google News News By Tag * Pain * Neuropathic * Treatment * Pipeline * 2010-19 * Drugs * Drug * Neurogesxastellas * Qutenza * Powerpoint * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Neuropathic Pain Market Forecast: New research report available at Fast Market ResearchNew Pharmaceuticals research report from Datamonitor is now available from Fast Market Research
At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaicin patch; NeurogesX/Astellas) Features and benefits * In depth analysis of historic (2005-09) and future (2010-19) seven major market prescription sales dynamics. * Includes neuropathic pain and country-specific sales forecasts for key brands, generics and pipeline drugs in the seven major markets to 2019. Highlights The neuropathic pain market is expected to achieve peak sales of $4.1bn over the forecast period (2010-19) across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). In addition to existing brands expanding into new regions, Datamonitor forecasts a total of eight pipeline candidates to enter the neuropathic pain market over the forecast period (2010-19) across the seven major markets. The broad label approval of Nucynta ER (extended-release tapentadol; Johnson & Johnson/Grunenthal) Your key questions answered * What will be the impact of major generic launches to the neuropathic pain market and what are the implications to prospective players? * What are the most promising drug candidates in development for the potential treatment of neuropathic pain? * What is the expected uptake of topical reformulations for neuropathic pain? * What is the commercial potential of Qutenza (8% capsaicin patch; NeurogesX/Astellas) For more information or to purchase this report, go to: - http://www.fastmr.com/ Report Table of Contents: OVERVIEW Summary OVERVIEW This product contains forecasts for neuropathic pain drugs across the seven major markets from 2010 to 2019. It has been designed for delivery in an excel data pack format, but for more detail about this disease area please see the accompanying Pipeline and Commercial Insight: Neuropathic Pain Word document and PowerPoint executive presentation (HC00019-001) The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative. Please select the data pack option from the download menu at the side of the page to access the model. Introduction Highlights Features and benefits Your key questions answered Forecasting Methodology The forecasting model: General event information: Event selection and quantification: Event parameters: Disclaimer About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|